Skip to main content

Table 2 Impact of CVVH treatment on whole group

From: Early continuous veno-venous haemofiltration in the management of severe acute pancreatitis complicated with intra-abdominal hypertension: retrospective review of 10 years' experience

 

Treatment

 
 

CVVH n = 75

no CVVH n = 55

p value

Demographics

Age, years

44.7 ± 13.9

51.5 ± 16.6

NS

 

Male, n (%)

65 (86.7%)

31 (56.4%)

 
 

Time from the first symptoms to hospitalization, median hours (IQR)

16 (26.8 to 3.8)

19.5 (48 to 11.5)

NS

 

APACHE II at admission, points

7.8 ± 4.1

7.5 ± 4.8

NS

 

IAP on admission, mmHg

14.2 ± 4.0

11.8 ± 3.0

0.048

 

SOFA on admission, points

2.4 ± 2.2

2.2 ± 1.9

NS

 

Necrotizing SAP, n (%)

62 (82.7%)

28 (50.9%)

<0.001

 

MODS, n (%)

70 (93.3%)

53 (96.3%)

NS

Organ dysfunctions

Renal dysfunction, n (%)

32 (42.7%)

15 (27.3%)

NS

 

Pulmonary dysfunction, n (%)

12 (16.0%)

5 (9.1%)

NS

 

Liver dysfunction, n (%)

12 (16.0%)

6 (10.9%)

NS

 

Cardiovascular, n (%)

6 (8%)

3 (5.5%)

NS

 

Hematologic, n (%)

5 (6.7%)

4 (7.2%)

NS

 

Neurologic, n (%)

15 (20%)

6 (10.9%)

NS

Complications

Metabolic acidosis, n (%)

24 (32%)

7 (12.7%)

0.013

 

Pleural effusion, n (%)

47 (62.7%)

14 (25.5%)

<0.001

 

Pneumonia, n (%)

31 (41.3%)

5 (9.1%)

<0.001

 

Atelectasis, n (%)

11 (14.7%)

2 (3.6%)

0.043

 

Pancreatic/peripancreatic infection, n (%)

21 (28%)

16 (29.1%)

NS

 

Surgical intervention, n (%)

21 (28%)

15 (27.3%)

NS